SCHEMBL624477

SCHEMBL624477

CC(C)COc1cc(N2CCN(C(=O)c3nc4ccccc4n3C)CC2)ncn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
PDE10A Q9Y233 3/20 0.43
ALDH1A1 P00352 4/20 0.41
TSHR P16473 2/20 0.41
MGLL Q99685 1/20 0.40
HSD17B10 Q99714 2/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622627 0.84 DRD2 (0.49) MEN1KMT2AALDH1A1TSHRHSD17B10
SCHEMBL624277 0.83 PDE10A (0.47) MEN1KMT2APDE10AALDH1A1HSD17B10
SCHEMBL623189 0.81 PTK2 (0.51) MEN1KMT2ATSHRMGLLPOLB
SCHEMBL624496 0.81 TSHR (0.53) MEN1KMT2AALDH1A1TSHRMGLL
SCHEMBL624539 0.80 MGLL (0.44) MEN1KMT2AALDH1A1MGLLSMN1; SMN2
SCHEMBL622626 0.80 DRD2 (0.52) MEN1KMT2AALDH1A1TSHRMGLL
SCHEMBL624636 0.80 ALDH1A1 (0.58) ALDH1A1TSHRHSD17B10ALOX15SMN1; SMN2
SCHEMBL622565 0.80 MGLL (0.43) MEN1KMT2AALDH1A1TSHRMGLL
SCHEMBL624350 0.79 PTGS1 (0.43) MEN1KMT2AALDH1A1TSHRMGLL
SCHEMBL623777 0.78 P2RY12 (0.46) TSHRMGLLHSD17B10ALOX15NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G MEN1 4301/4885KMT2A 1431/4885PDE10A 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.